The scientist’s investigation covers issues in Debrisoquine, Internal medicine, Pharmacology, Genetics and Biochemistry. His studies in Debrisoquine integrate themes in fields like Debrisoquin, Polymorphism and Hydroxylation. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Endocrinology and Pathology.
His work on Acetaminophen as part of general Pharmacology research is frequently linked to In patient, bridging the gap between disciplines. His Genetics research focuses on Molecular biology and how it connects with Humanized mouse, Peptide sequence and COS cells. His research investigates the link between Biochemistry and topics such as Metabolomics that cross with problems in Transcriptome, Lipid metabolism, Toxicity and Physiology.
His primary scientific interests are in Pharmacology, Internal medicine, Endocrinology, Biochemistry and Metabolite. Jeffrey R. Idle has included themes like Metabolism, Toxicity, Debrisoquine and Hydroxylation in his Pharmacology study. Jeffrey R. Idle usually deals with Debrisoquine and limits it to topics linked to Allele and Genotype, Restriction fragment length polymorphism and Genotyping.
His Internal medicine research is multidisciplinary, incorporating perspectives in Pharmacogenetics and Oncology. He interconnects Peroxisome proliferator-activated receptor, Trimethylamine and Nicotine in the investigation of issues within Endocrinology. His Metabolite study incorporates themes from Urine, Chromatography and Nifedipine.
The scientist’s investigation covers issues in Metabolomics, Biochemistry, Pharmacology, Internal medicine and Endocrinology. His Metabolomics research incorporates themes from Metabolite, Urine, Tandem mass spectrometry and Xenobiotic. His study looks at the relationship between Metabolite and fields such as Metabolism, as well as how they intersect with chemical problems.
His Pharmacology research integrates issues from Pregnane X receptor and Toxicity. Internal medicine is frequently linked to Gastroenterology in his study. His Endocrinology research incorporates elements of Biomarker, Peroxisome proliferator-activated receptor, Fatty acid, Liver disease and Peroxisome.
Metabolomics, Biochemistry, Pharmacology, Internal medicine and Metabolite are his primary areas of study. Jeffrey R. Idle combines subjects such as Pimelic acid, Urine, Xanthine and Metabolism with his study of Metabolomics. His biological study spans a wide range of topics, including Tandem mass spectrometry and Mass spectrometry.
His studies deal with areas such as Pregnane X receptor and Toxicity as well as Pharmacology. His Internal medicine research includes themes of Gastroenterology and Endocrinology. Jeffrey R. Idle has researched Drug metabolism in several fields, including Phenacetin, Polymorphism, Debrisoquine, Hydroxylation and Xenobiotic.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Polymorphic hydroxylation of debrisoquine in man
A Mahgoub;L.G Dring;J.R Idle;R Lancaster.
The Lancet (1977)
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
D A Evans;A Mahgoub;T P Sloan;J R Idle.
Journal of Medical Genetics (1980)
Nomenclature for human CYP2D6 alleles.
A K Daly;J Brockmoller;F Broly;M Eichelbaum.
Pharmacogenetics (1996)
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer
Riad Ayesh;Jeffrey R. Idle;James C. Ritchie;Michael J. Crothers.
Nature (1984)
The role of individual human cytochromes P450 in drug metabolism and clinical response.
Suzanne Cholerton;Ann K. Daly;Jeffrey R. Idle.
Trends in Pharmacological Sciences (1992)
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Hirokazu Furuya;Pedro Fernandez-salguero;Wendy Gregory;Heather Taber.
Pharmacogenetics (1995)
Metabolism of melatonin by human cytochromes p450.
Xiaochao Ma;Jeffrey R Idle;Kristopher W Krausz;Frank J Gonzalez.
Drug Metabolism and Disposition (2005)
Mutant debrisoquine hydroxylation genes in Parkinson's disease
M. Armstrong;A.K. Daly;S. Cholerton;J.R. Idle.
The Lancet (1992)
Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
Vidar M. Steen;Ole A. Andreassen;Ann K. Daly;Toril Tefre.
Pharmacogenetics (1995)
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.
R R Shah;N S Oates;J R Idle;R L Smith.
BMJ (1982)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institutes of Health
National Institutes of Health
Newcastle University
Pennsylvania State University
National Institutes of Health
Imperial College London
National Institutes of Health
Georgetown University
National Institutes of Health
University of Extremadura
Wenzhou University
FX Palo Alto Laboratory
Radboud University Nijmegen
Panasonic (Japan)
Lund University
University of Bergen
University of California, San Francisco
National Health Research Institutes
University of Luxembourg
Defence Science and Technology Laboratory
University of California, Los Angeles
University of Queensland
Osaka University
Stavanger University Hospital
University of Kentucky
Catholic University of the Sacred Heart